γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma-Reference-Cited by-同舟云学术

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Published:2019-09-25 Issue:19 Volume:134 Page:1585-1597
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pont Margot J.¹^ORCID,Hill Tyler¹^ORCID,Cole Gabriel O.¹^ORCID,Abbott Joe J.¹,Kelliher Jessica¹,Salter Alexander I.¹²^ORCID,Hudecek Michael³,Comstock Melissa L.¹,Rajan Anusha¹^ORCID,Patel Bharvin K. R.⁴,Voutsinas Jenna M.¹,Wu Qian¹,Liu Lingfeng¹^ORCID,Cowan Andrew J.²,Wood Brent L.²,Green Damian J.¹²^ORCID,Riddell Stanley R.¹²

Affiliation:

1. Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Department of Medicine, University of Washington, Seattle, WA;

3. Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; and

4. Eli Lilly and Company, Indianapolis, IN

Abstract

Despite notably high response rates to B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells in multiple myeloma, few patients have a sustained, very good partial or complete response. This article presents a novel strategy to increase the efficacy of BCMA-directed CAR T-cell therapy and shows that γ-secretase inhibitors improve the efficacy of BCMA CAR T cells by increasing BCMA expression and reducing soluble BCMA.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/19/1585/1505398/bloodbld2019000050.pdf

Reference62 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;N Engl J Med,1996

2. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321 [published correction appears in J Clin Oncol. 2006;24(17):2687];Barlogie;J Clin Oncol,2006

3. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010;Bladé;Blood,2010

4. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

5. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma;Harousseau;Stem Cells,1995

Cited by 230 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment;Bioactive Materials;2024-12

2. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

3. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies;Biomedicine & Pharmacotherapy;2024-09

4. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features;Cellular Oncology;2024-08-27

5. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma;Frontiers in Oncology;2024-08-08